Advertisement
Advertisement
U.S. Markets open in 2 hrs 52 mins
Advertisement
Advertisement
Advertisement
Advertisement

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.05-0.08 (-0.79%)
At close: 04:00PM EST
9.50 -0.55 (-5.47%)
After hours: 07:30PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.13
Open10.14
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range9.56 - 10.14
52 Week Range2.36 - 12.85
Volume100,155
Avg. Volume127,103
Market Cap130.745M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-33.68
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.80
  • Business Wire

    Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

    BOSTON, November 10, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

  • Business Wire

    Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

    BOSTON, Mass., November 09, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming Jefferies London Healthcare Conference on Wednesday, November 16th at

  • Business Wire

    Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting

    BOSTON, November 07, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share preclinical data for STAR-0215 in a presentation titled "Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215" at the 2022 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Louisville, Kentucky.

Advertisement
Advertisement